II. Keynote

IV. Preclinical Section

     1. Preclinical Strategy for Evaluation of Novel Mechanism Compounds

          .

     2. Unique Challenges in  Study Designs

           .

     3. Evaluation of Biologics

                 .

V. Clinical Section

     1. Approaches to identify and classify AEs and aberrant behaviors related to abuse, misuse and  diversion during clinical drug development

             .

     2. Statistical Considerations for Human Abuse Potential Studies

                       .

     3. Assessments of Physical Dependence in Clinical Setting

                           .

VI. Post-Marketing Section

Slides (in pdf format)

Advancements in Abuse Potential Assessments 
- Building on the FDA Draft Guidance for Industry